MEI Pharma is a pharmaceutical company focused on using its development and oncology capabilities to identify and develop therapies for the treatment of cancer. Co.'s existing drug candidate pipeline includes: Zandelisib, an oral, once-daily, selective phosphatidylinositol 3-kinase delta inhibitor for the treatment of B-cell malignancies; Voruciclib, an orally administered cyclin-dependent kinase inhibitor; ME-344, a tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate; and Pracinostat, an oral histone deacetylase inhibitor being evaluated in patients with high or very high-risk myelodysplastic syndrome who are previously untreated with hypomethylating agents. The MEIP stock yearly return is shown above.
The yearly return on the MEIP stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MEIP annual return calculation with any dividends reinvested as applicable (on ex-dates).
|